Sanofi (SNY) Competitors

Sanofi (NASDAQ:SNY) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Does the media favor SNY or NVS?

In the previous week, Novartis had 6 more articles in the media than Sanofi. MarketBeat recorded 26 mentions for Novartis and 20 mentions for Sanofi. Novartis' average media sentiment score of 1.33 beat Sanofi's score of 0.88 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	9 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	22 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, SNY or NVS?

Sanofi has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.

Is SNY or NVS more profitable?

Novartis has a net margin of 25.64% compared to Sanofi's net margin of 21.47%. Novartis' return on equity of 41.08% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	21.47%	16.86%	9.63%
Novartis	25.64%	41.08%	16.83%

Do analysts prefer SNY or NVS?

Sanofi currently has a consensus target price of $62.00, indicating a potential upside of 36.91%. Novartis has a consensus target price of $123.50, indicating a potential downside of 4.03%. Given Sanofi's stronger consensus rating and higher probable upside, research analysts clearly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.22
Novartis	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

Which has preferable earnings & valuation, SNY or NVS?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$45.74B	2.43	$6.02B	$4.16	10.89
Novartis	$50.32B	5.40	$11.94B	$6.87	18.73

Do insiders and institutionals have more ownership in SNY or NVS?

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Is SNY or NVS a better dividend stock?

Sanofi pays an annual dividend of $1.59 per share and has a dividend yield of 3.5%. Novartis pays an annual dividend of $2.60 per share and has a dividend yield of 2.0%. Sanofi pays out 38.2% of its earnings in the form of a dividend. Novartis pays out 37.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.